Document is current
Any future updates will be listed below
-
Authors
Scholz, Paul https://orcid.org/0009-0003-6866-0689
Thompson, Jared
Crosby, Kadin T. https://orcid.org/0009-0001-0201-5340
Fauth, Torsten
Krah, Nathan M. https://orcid.org/0009-0003-8297-7359
Schlauderaff, Grant https://orcid.org/0000-0003-0365-9073
Back, Robin https://orcid.org/0009-0002-1730-7941
Berkheimer, Zachary A.
Jolley, Alivia https://orcid.org/0009-0005-7520-5494
Sombroek, Dirk
Medert, Rebekka https://orcid.org/0000-0001-7571-3732
Zurek, Christian
Dmytrenko, Oleg https://orcid.org/0000-0002-1165-6836
Wilson, Emily
Schut, Friso T.
Rutter, Jared https://orcid.org/0000-0002-2710-9765
Zhang, Xiaoyang https://orcid.org/0000-0002-0031-0290
Krohn, Michael
Jackson, Ryan N. https://orcid.org/0000-0001-7403-3794
Beisel, Chase L. https://orcid.org/0000-0003-0650-9943
Liu, Yang https://orcid.org/0000-0002-3889-9707
- License Information
-
More Information
Article History
Received: 11 March 2025
Accepted: 26 March 2026
First Online: 6 May 2026
Competing interests
: BRAIN Biotech AG has filed patent applications that cover the GeCas12a2 nuclease sequence (WO 2022/017633) and its use for cell depletion (WO 2023/139096), with P.S., C.Z. and M.K. as inventors. The Helmholtz Centre for Infection Research and Utah State University have filed provisional patent applications on Cas12a2 and its applications (WO 2022/253903A1), with O.D., R.N.J. and C.L.B. as inventors. C.L.B. is a co-founder and scientific advisor to Locus Biosciences, a co-founder and officer of Leopard Biosciences GmbH, and scientific advisor to Benson Hill. C.Z. is an employee of BRAIN Biotech. A.G., P.S., T.F., R.B., D.S. and R.M. are employees of Akribion Therapeutics GmbH. M.K. is a co-founder and co-CEO of Akribion Therapeutics GmbH. The remaining authors declare no competing interests.
